Case Study:
Tyers, Mike
As one of Canada’s leaders in functional genomics, Professor Mike Tyers has helped advance our understanding of the genetic and biochemic…
READ MORE ALL CASE STUDIES
Millipore Corporation and BioOutsource Ltd to collaborate
21 July 2010
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, jointly announced with BioOutsource Ltd that they have formed a strategic alliance. The industry knowledge, scientific strength and modern facilities of the two companies combine to offer a world-class biosafety testing partner that biopharmaceutical manufacturers can rely on as an extension of their own quality assurance teams. This collaboration will enable Millipore and BioOutsource to bring a full range of biosafety services to industrial clients who seek a world-class supplier.
The criticality of release testing for vaccine and biological products can create challenges for biopharmaceutical and pharmaceutical organizations, which, in turn, can lead to delays in product development and release. Through the combination of Millipore's state-of-the-art cGMP facility in Leiden, The Netherlands, and BioOutsource's custom-built cGMP facility in Glasgow, UK, biopharmaceutical manufacturers can feel confident that their drug products will be produced safely and successfully.
"This alliance offers manufacturers a new alternative for contract testing which will allow them to deploy their resources in other critical areas. For example, these resources can be refocused on drug development or manufacturing and ultimately reduce a product's time to market. The complementary nature of both companies' offerings means customers can benefit from a best-in-class biosafety portfolio, with technical and scientific strength second to none,"
says Andrew Bulpin, Ph.D., Millipore's Vice President, Services and Solutions and Upstream Processing.
"This new joint offering is comprehensive, providing scientific expertise and proven industry experience. Our goals are to help the industry reduce time spent on the development process as well as provide a reliable resource for product release testing to specification within a cGMP environment. This can also lower the necessity of a company maintaining its own cGMP quality control facility within its organization, thus decreasing overall costs dramatically,"
says Gerry MacKay, Chief Executive Officer, BioOutsource.
For further media information contact Karen Marinella Hall, Director of Corporate Communications, Millipore Corporation E: karen_hall@millipore.com.
